- Home
- INTS vs MDCX Comparison
INTS vs MDCX Comparison
Compare INTS & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INTS | MDCX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 15.9M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | INTS | MDCX |
|---|---|---|
| Price | $4.02 | $0.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $38.00 | $14.50 |
| AVG Volume (30 Days) | 29.3K | ★ 4.5M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.15 |
| 52 Week High | $8.06 | $3.05 |
Technical Indicators
Market Signals| Indicator | INTS | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 42.07 | 26.98 |
| Support Level | $3.95 | N/A |
| Resistance Level | $5.09 | $0.36 |
| Average True Range (ATR) | 0.25 | 0.02 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 4.24 | 8.08 |
Price Performance
Historical ComparisonAbout INTS Intensity Therapeutics Inc.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.